Large pharmaceutical companies cut more than 22,000 jobs in 2025 as a $300 billion patent cliff approaches, signaling a broad industry correction in workforce size and cost structure ahead of significant revenue losses. These layoffs are not simply cost containment. They reflect deeper strategic recalibration, and companies must respond with…
When Congress passed the Inflation Reduction Act in 2022, most headlines focused on lower drug prices for Medicare beneficiaries. Far less attention has been paid to how compressing the product prime earning cycle is reshaping pharmaceutical development and commercialization strategy. Pharmaceutical leaders need an alternative approach to the blockbuster model…
Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…
Across the globe, pharma companies are experiencing new levels of price resistance and competitive pressure. No one wants to spend more than they already do – unless they’re given a compelling reason. The only counter to that pressure is compelling evidence of differentiated value. Once considered nice-to-have, real-world evidence (RWE)…
In a previous column, I discussed how pharmaceutical and medical device companies are adapting their commercial model approaches in critical areas to address growing economic, market and other competitive pressures. This adaptation is underscored in our new Numerof & Associates 2023 Commercial Model Report, which reveals the strategic changes that…
Clinical research networks continue to play a pivotal role in supporting pipeline development. However, the importance of these networks extends well beyond the conduct of clinical trials. Clinical investigators can support market conditioning, serve as important levers for informing evidence-based clinical pathways/guidelines, and aid in the generation of real-world evidence…
